ONO-3951 Phase II Study

A multicenter, randomized, double-blind, placebo-controlled, parallel-group study in subjects with irritable bowel syndrome with diarrhea

Status

Unknown

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221823

Enrollment

240

Registered

2012-06-13

Start date

2012-06-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome with diarrhea(IBS-D)

Interventions

investigational material(s) Generic name etc : ONO-3951 INN of investigational material : Asimadoline Therapeutic category code : 239 Other agents affecting digestive organs Dosage and Administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Subjects diagnosed with IBS-D based on the Rome III diagnostic criteria

Exclusion criteria

Exclusion criteria: 1. Presence or history of any of the organic gastrointestinal diseases

Design outcomes

Primary

Measure	Time frame
Percentage of subjects with improvement in abdominal pain	—

Secondary

Measure	Time frame
Percentage of subjects with improvement in stool frequency, etc.	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026